Faron's Webcast on BEXMAB Phase 1 Data and Bexmarilimab Updates

Faron Pharmaceuticals, a biopharmaceutical firm specializing in innovative immunotherapies, has announced the scheduling of a virtual BEXMAB study update session. The event, which will not require any special software or plugins to join, is set to take place on March 19, 2024, at 11:00 EET/9:00 am GMT. The meeting will feature discussions on the latest findings from the BEXMAB clinical trial involving patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), focusing on the long-term effectiveness of bexmarilimab when combined with standard care treatments.

Key speakers at the event will include Dr. Mika Kontro, an Associate Professor at the University of Helsinki and the principal investigator of the BEXMAB study, Dr. Maija Hollmen, the Chief Scientific Officer at Faron, Dr. Juho Jalkanen, the Chief Operating Officer at Faron, and other members of the company's senior leadership. The session will provide insights into myeloid leukemia, the unique mechanism of action of bexmarilimab, and the company's insights into the drug's efficacy in both the short and long term. Faron will also discuss the future development plans for bexmarilimab and its business prospects. The event will be interactive, with a Q&A segment, and parts of the discussion will be conducted in Finnish, followed by a summary in English.

Bexmarilimab, Faron's proprietary immunotherapy, is currently under investigation in a Phase 1/2 clinical trial. The drug is designed to target Clever-1, a receptor that is highly expressed in AML and MDS cells and is associated with poor treatment outcomes. By binding to Clever-1, bexmarilimab aims to reprogram myeloid cells, potentially enhancing the body's immune response against cancer cells and improving the effectiveness of standard treatments.

Faron Pharmaceuticals is a global clinical-stage company dedicated to developing novel therapies for cancer treatment. The company's lead product, bexmarilimab, is a humanized antibody that targets myeloid cell function to counteract cancer's immunosuppressive mechanisms. Faron is exploring the potential of bexmarilimab in combination with standard treatments for hematological cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!